{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:39:55Z","timestamp":1790667595758,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11899-019-00543-7","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T07:02:58Z","timestamp":1566975778000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors"],"prefix":"10.1007","volume":"14","author":[{"given":"Marjan","family":"Yaghmaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia CS","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"issue":"5894","key":"543_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300(5894):765\u20137.","journal-title":"Nature."},{"issue":"252","key":"543_CR2","doi-asserted-by":"publisher","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","volume":"6","author":"L Ma","year":"2014","unstructured":"Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. A therapeutically targetable mechanism of BCR-ABL\u2013independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014;6(252):252ra121.","journal-title":"Sci Transl Med"},{"issue":"1","key":"543_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17(1):49.","journal-title":"Mol Cancer"},{"issue":"3","key":"543_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ccr.2014.08.010","volume":"26","author":"J Radich","year":"2014","unstructured":"Radich J. Structure, function, and resistance in chronic myeloid leukemia. Cancer Cell. 2014;26(3):305\u20136.","journal-title":"Cancer Cell"},{"issue":"17","key":"543_CR5","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554\u201360.","journal-title":"Blood."},{"issue":"4","key":"543_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494\u2013500.","journal-title":"Blood."},{"issue":"24","key":"543_CR7","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"issue":"19","key":"543_CR8","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898\u2013905.","journal-title":"Blood."},{"issue":"11","key":"543_CR9","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018\u201329.","journal-title":"Lancet Oncol"},{"issue":"10","key":"543_CR10","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","volume":"99","author":"HM Kantarjian","year":"2002","unstructured":"Kantarjian HM, Cortes J, O\u2019Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase. Blood. 2002;99(10):3547\u201353.","journal-title":"Blood."},{"issue":"11","key":"543_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","journal-title":"N Engl J Med"},{"issue":"16","key":"543_CR12","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1002\/cncr.25123","volume":"116","author":"G Saglio","year":"2010","unstructured":"Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116(16):3852\u201361.","journal-title":"Cancer."},{"issue":"10","key":"543_CR13","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001. Blood. 2002;99(10):3530\u20139.","journal-title":"Blood."},{"issue":"1","key":"543_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","volume":"20","author":"T Hughes","year":"2006","unstructured":"Hughes T, Branford S. Molecular monitoring of BCR\u2013ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006;20(1):29\u201341.","journal-title":"Blood Rev"},{"issue":"9","key":"543_CR15","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","volume":"104","author":"S Branford","year":"2004","unstructured":"Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104(9):2926\u201332.","journal-title":"Blood."},{"issue":"14","key":"543_CR16","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733\u20136.","journal-title":"Blood."},{"issue":"10","key":"543_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.18553\/jmcp.2014.20.10.1006","volume":"20","author":"D Trivedi","year":"2014","unstructured":"Trivedi D, Landsman-Blumberg P, Darkow T, Smith D, McMorrow D, Mullins CD. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Pharm. 2014;20(10):1006\u201315.","journal-title":"J Manag Care Pharm"},{"issue":"23","key":"543_CR18","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"15","key":"543_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423\u201332.","journal-title":"N Engl J Med"},{"issue":"8","key":"543_CR20","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"J Steegmann","year":"2016","unstructured":"\u2022 Steegmann J, Baccarani M, Breccia M, Casado L, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648. This is the clinical practive guidelines for CML issued by ELN.","journal-title":"Leukemia."},{"issue":"4","key":"543_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"\u2022\u2022 Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol \/Oncol Clinics. 2017;31(4):589\u2013612. This study used NGS for detection of ABL1 KD mutations but also detected compound mutations and recognized specific resistance profiles.","journal-title":"Hematol \/Oncol Clinics"},{"issue":"6","key":"543_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"543_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor\u2013resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489\u201398.","journal-title":"Blood."},{"issue":"3","key":"543_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/leu.2014.245","volume":"29","author":"AM Eiring","year":"2015","unstructured":"Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2015;29(3):586\u201397.","journal-title":"Leukemia."},{"issue":"7","key":"543_CR25","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.bbapap.2012.12.009","volume":"1834","author":"AJ Lamontanara","year":"2013","unstructured":"Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O. Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochim Biophys Acta Proteins Proteom. 2013;1834(7):1449\u201359.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"10","key":"543_CR26","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O\u2019brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20(10):1767\u201373.","journal-title":"Leukemia."},{"issue":"8","key":"543_CR27","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U, Paschka P, M\u00fcller MC, Kreil S, et al. Response and resistance in 300 patients with BCR-ABL\u2013positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005;103(8):1659\u201369.","journal-title":"Cancer"},{"issue":"5","key":"543_CR28","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208\u201315.","journal-title":"Blood."},{"issue":"2","key":"543_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117\u201325.","journal-title":"Cancer Cell"},{"issue":"10","key":"543_CR30","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, Ding P-R, Ashby CR Jr, Chen Z-S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255\u201368.","journal-title":"Leuk Res"},{"issue":"6","key":"543_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood."},{"issue":"10","key":"543_CR32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/14737159.2016.1227243","volume":"16","author":"Cecilia Ching Sze Yeung","year":"2016","unstructured":"Yeung CCS, Egan D, Radich JP. Molecular monitoring of chronic myeloid leukemia: present and future. Expert. Rev. Mol. Diagn. 2016;16(10):1083\u201391.","journal-title":"Expert Review of Molecular Diagnostics"},{"issue":"35","key":"543_CR33","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"543_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10\u201320.","journal-title":"Leuk Res"},{"issue":"9","key":"543_CR35","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"Jerald P. Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2018;16(9):1108\u201335.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"19","key":"543_CR36","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818\u201324.","journal-title":"Blood."},{"issue":"4","key":"543_CR37","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","volume":"13","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Quint\u00e1s-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res. 2007;13(4):1089\u201397.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"543_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28\u201339.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"543_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1046\u201351.","journal-title":"Nat Biotechnol"},{"issue":"5531","key":"543_CR40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876\u201380.","journal-title":"Science."},{"issue":"2","key":"543_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","volume":"25","author":"C Talati","year":"2018","unstructured":"\u2022 Talati C, Pinilla-Ibarz J. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents. Curr Opin Hematol. 2018;25(2):154\u201361. This reviews definitions of resistance.","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"543_CR42","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2015.168","volume":"29","author":"TP Hughes","year":"2015","unstructured":"Hughes TP, Saglio G, Quintas-Cardama A, Mauro MJ, Kim DW, Lipton JH, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015;29(9):1832\u20138.","journal-title":"Leukemia."},{"issue":"Suppl 2","key":"543_CR43","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1007\/s00277-015-2323-1","volume":"94","author":"A Hochhaus","year":"2015","unstructured":"Hochhaus A, Ernst T, Eigendorff E, La Rosee P. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. Ann Hematol. 2015;94(Suppl 2):S133\u201340.","journal-title":"Ann Hematol"},{"issue":"16","key":"543_CR44","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2012-07-442871","volume":"121","author":"CC Smith","year":"2013","unstructured":"Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013;121(16):3165\u201371.","journal-title":"Blood."},{"issue":"47","key":"543_CR45","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003;22(47):7389\u201395.","journal-title":"Oncogene."},{"issue":"1","key":"543_CR46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276\u201383.","journal-title":"Blood."},{"issue":"2","key":"543_CR47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","volume":"10","author":"CA Eide","year":"2015","unstructured":"Eide CA, O\u2019Hare T. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr Hematol Malig Rep. 2015;10(2):158\u201366.","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"543_CR48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428\u201342.","journal-title":"Cancer Cell"},{"issue":"3","key":"543_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489\u201398.","journal-title":"Blood."},{"issue":"3","key":"543_CR50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428\u201342.","journal-title":"Cancer Cell"},{"issue":"2","key":"543_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Br\u00fcggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129\u201341.","journal-title":"Cancer Cell"},{"issue":"12","key":"543_CR52","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin J. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765\u20139.","journal-title":"Br J Cancer"},{"issue":"45","key":"543_CR53","doi-asserted-by":"publisher","first-page":"35631","DOI":"10.1074\/jbc.M005401200","volume":"275","author":"BB Brasher","year":"2000","unstructured":"Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem. 2000;275(45):35631\u20137.","journal-title":"J Biol Chem"},{"issue":"56","key":"543_CR54","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1038\/sj.onc.1205017","volume":"20","author":"K Dorey","year":"2001","unstructured":"Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T, et al. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene. 2001;20(56):8075\u201384.","journal-title":"Oncogene."},{"issue":"26","key":"543_CR55","doi-asserted-by":"publisher","first-page":"18292","DOI":"10.1074\/jbc.M801337200","volume":"283","author":"N Vajpai","year":"2008","unstructured":"Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Grzesiek S, et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib. J Biol Chem. 2008;283(26):18292\u2013302.","journal-title":"J Biol Chem"},{"issue":"51","key":"543_CR56","doi-asserted-by":"publisher","first-page":"19466","DOI":"10.1073\/pnas.0609239103","volume":"103","author":"BJ Skaggs","year":"2006","unstructured":"Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci. 2006;103(51):19466\u201371.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"543_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol. 2009;27(3):469\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"543_CR58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u201312.","journal-title":"Cancer Cell"},{"issue":"22","key":"543_CR59","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome\u2013positive leukemias. N Engl J Med. 2012;367(22):2075\u201388.","journal-title":"N Engl J Med"},{"key":"543_CR60","doi-asserted-by":"crossref","unstructured":"Danisz K, Blasiak J. Role of anti-apoptotic pathways activated by BCR\/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Acta Biochim Pol. 2013;60(4).","DOI":"10.18388\/abp.2013_2014"},{"issue":"7","key":"543_CR61","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242\u20139.","journal-title":"Blood."},{"issue":"5","key":"543_CR62","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood."},{"issue":"10","key":"543_CR63","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"R Larson","year":"2012","unstructured":"Larson R, Hochhaus A, Hughes T, Clark R, Etienne G, Kim D, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197\u2013203.","journal-title":"Leukemia."},{"issue":"9","key":"543_CR64","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841\u201351.","journal-title":"Lancet Oncol"},{"issue":"9","key":"543_CR65","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"\u2022\u2022 Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(9):1108\u201335. This is the clinical practice guidelines for CML issued by NCCN.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"543_CR66","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-016-0303-8","volume":"11","author":"CC Yeung","year":"2016","unstructured":"Yeung CC, Egan D, Radich J. New methodologies in the molecular monitoring of CML. Curr Hematol Malig Rep. 2016;11(2):94\u2013101.","journal-title":"Curr Hematol Malig Rep"},{"issue":"24","key":"543_CR67","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374\u20139.","journal-title":"Clin Cancer Res"},{"issue":"suppl_7","key":"543_CR68","doi-asserted-by":"publisher","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","volume":"23","author":"M Baccarani","year":"2012","unstructured":"Baccarani M, Pileri S, Steegmann J-L, Muller M, Soverini S, Dreyling M, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl_7):vii72\u2013vii7.","journal-title":"Ann Oncol"},{"issue":"5","key":"543_CR69","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","volume":"141","author":"K Machova Polakova","year":"2015","unstructured":"Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887\u201399.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"543_CR70","doi-asserted-by":"publisher","first-page":"21982","DOI":"10.18632\/oncotarget.8010","volume":"7","author":"S Soverini","year":"2016","unstructured":"\u2022\u2022 Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, et al. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget. 2016;7(16):21982\u201390. This study used NGS for detection of ABL1 KD mutations and demonstrated improved sensitivity.","journal-title":"Oncotarget."},{"issue":"5","key":"543_CR71","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.leu.2402889","volume":"17","author":"N Von Bubnoff","year":"2003","unstructured":"Von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia. 2003;17(5):829\u201338.","journal-title":"Leukemia."},{"issue":"11","key":"543_CR72","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin A, La Rosee P, M\u00fcller M, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190\u20136.","journal-title":"Leukemia."},{"issue":"9","key":"543_CR73","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Polakova KM, Brouckova A, Horner D, Iacono M, et al. Unraveling the complexity of tyrosine kinase inhibitor\u2013resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122(9):1634\u201348.","journal-title":"Blood."},{"issue":"19","key":"543_CR74","doi-asserted-by":"publisher","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","volume":"65","author":"DJ Barnes","year":"2005","unstructured":"Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65(19):8912\u20139.","journal-title":"Cancer Res"},{"issue":"8","key":"543_CR75","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496\u20139.","journal-title":"Blood."},{"issue":"5","key":"543_CR76","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc799","volume":"2","author":"T Skorski","year":"2002","unstructured":"Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer. 2002;2(5):351\u201360.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"543_CR77","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254\u201364.","journal-title":"J Clin Invest"},{"issue":"4","key":"543_CR78","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3324\/haematol.2009.014712","volume":"95","author":"TD Kim","year":"2010","unstructured":"Kim TD, T\u00fcrkmen S, Schwarz M, Koca G, Nogai H, Bommer C, et al. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica. 2010;95(4):582\u20138.","journal-title":"Haematologica."},{"issue":"6","key":"543_CR79","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310.","journal-title":"Blood."},{"issue":"3","key":"543_CR80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","volume":"93","author":"K Yang","year":"2015","unstructured":"Yang K, Fu L-w. Mechanisms of resistance to BCR\u2013ABL TKIs and the therapeutic strategies: a review. Crit Rev Oncol Hematol. 2015;93(3):277\u201392.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"543_CR81","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53(1):615\u201327.","journal-title":"Annu Rev Med"},{"issue":"9","key":"543_CR82","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879\u201394.","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"543_CR83","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28(16):2761\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"543_CR84","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110(12):4064\u201372.","journal-title":"Blood."},{"issue":"24","key":"543_CR85","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15(24):7519\u201327.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"543_CR86","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/leu.2015.35","volume":"29","author":"L Lu","year":"2015","unstructured":"Lu L, Saunders V, Leclercq T, Hughes T, White D. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia. 2015;29(8):1792\u20134.","journal-title":"Leukemia."},{"issue":"3","key":"543_CR87","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","volume":"95","author":"L Eadie","year":"2014","unstructured":"Eadie L, Hughes T, White D. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther. 2014;95(3):294\u2013306.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"543_CR88","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/leu.2014.38","volume":"28","author":"A Giannoudis","year":"2014","unstructured":"Giannoudis A, Davies A, Harris R, Lucas C, Pirmohamed M, Clark R. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia. 2014;28(6):1360\u20133.","journal-title":"Leukemia."},{"issue":"5","key":"543_CR89","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/BF02353475","volume":"24","author":"GR Wilkinson","year":"1996","unstructured":"Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996;24(5):475\u201390.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"10","key":"543_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000990","volume":"2","author":"NL Komarova","year":"2007","unstructured":"Komarova NL, Wodarz D. Effect of cellular quiescence on the success of targeted CML therapy. PLoS One. 2007;2(10):e990.","journal-title":"PLoS One"},{"issue":"7","key":"543_CR91","first-page":"3025","volume":"17","author":"K Shah","year":"2016","unstructured":"Shah K, Parikh S, Rawal R. Tyrosine kinase inhibitors in Ph+ chronic myeloid leukemia therapy: a review. Asian Pac J Cancer Prev. 2016;17(7):3025\u201333.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"543_CR92","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","volume":"141","author":"KM Polakova","year":"2015","unstructured":"Polakova KM, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887\u201399.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-019-00543-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T16:33:41Z","timestamp":1650472421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-019-00543-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00543-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"28 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Yeung reports grants from OBI Pharmaceuticals and Pfizer outside the submitted work. Dr. Yaghmaie declares no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}